Augmedix (AUGX) Stock Price, News & Analysis

Company Overview

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $2.34 to $2.35
• 50-Day Range: $2.29 to $2.35
• 52-Week Range: $0.73 to $6.25
• Volume: 23,900 shs
• Average Volume: 635,746 shs
• Market Capitalization: $115.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.09
• Consensus Rating: Hold

AUGX Stock Analysis - Frequently Asked Questions

How have AUGX shares performed this year?

Augmedix's stock was trading at $5.85 at the beginning of 2024. Since then, AUGX stock has decreased by 59.8% and is now trading at $2.35.
View the best growth stocks for 2024 here.

How were Augmedix's earnings last quarter?

Augmedix, Inc. (NASDAQ:AUGX) released its earnings results on Monday, August, 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.04. The firm earned $13.66 million during the quarter, compared to analysts' expectations of $13.68 million. Augmedix had a negative trailing twelve-month return on equity of 182.36% and a negative net margin of 46.23%.

When did Augmedix IPO?

Augmedix (AUGX) raised $40 million in an initial public offering (IPO) on Tuesday, October 26th 2021. The company issued 10,000,000 shares at a price of $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street acted as the underwriters for the IPO.

Who are Augmedix's major shareholders?

Top institutional investors of Augmedix include Trium Capital LLP (2.41%). Insiders that own company stock include Paul Ginocchio, Emmanuel Krakaris, Ian Shakil and Saurav Chatterjee.
View institutional ownership trends.

How do I buy shares of Augmedix?

Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Augmedix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Augmedix investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 11/02/2024
• Next Earnings (Estimated): 11/04/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:AUGX
• CUSIP: N/A
• CIK: 1769804
• Web: www.augmedix.com
• Phone: 888-669-4885
• Fax: N/A
• Employees: 1,430
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.09
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +31.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,170,000.00
• Net Margins: -46.23%
• Pretax Margin: -46.10%
• Return on Equity: -182.36%
• Return on Assets: -43.21%

Debt

• Debt-to-Equity Ratio: 1.48
• Current Ratio: 1.66
• Quick Ratio: 1.66

Sales & Book Value

• Annual Sales: $51.58 million
• Price / Sales: 2.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 4.20

Miscellaneous

• Outstanding Shares: 48,968,000
• Free Float: 43,596,000
• Market Cap: $115.07 million
• Optionable: Optionable
• Beta: -0.22